.

Previous Requests July 2018

2 July 2018

889

SDCCG

 1. Does your CCG routinely fund the provision of bisphosphonates for postmenopausal women with primary breast cancer to reduce the risk of their cancer spreading to other parts of the body?

2. If your CCG does routinely fund bisphosphonates to reduce the risk of primary breast cancer spreading to other parts of the body, but is not routinely funding them for all postmenopausal women, how is eligibility defined? For example, women at increased risk of recurrence.

3. If your CCG does routinely fund bisphosphonates for postmenopausal women to reduce the risk of primary breast cancer spreading to other parts of the body, which bisphosphonates is it funding?  For example, zoledronic acid, ibandronic acid, sodium clodronate.

4. If your CCG does not routinely fund bisphosphonates for postmenopausal women to reduce the risk of primary breast cancer spreading to other parts of the body, what are its reasons for not doing so?

Click here for response
 2 July 2018

890

All CCGs 

 Q1: IVF provision

1a: In the financial year 2017/18 what was the total number of IVF, ICSI and FET cycles delivered on behalf of your CCG (separate volumes) and the total spend by the CCG.
1b: For the financial year 2017/18, please provide the per cycle price paid to ISP ‘s to deliver IVF, ICSI and FET cycles. (If you are unable to answer this for commercial reasons please answer 1c) 
1c: For each pathway of care below, please indicate the number of providers contracted by the CCG that fall into each price range according to the current cost per cycle.
1d: How many cycles of IVF (with or without ICSI) do you offer patients i.e. – 1 cycle, 3 cycles. Please describe your policy as to whether the cycles offered are fresh, frozen, or full cycles. In other words, do you count fresh/ frozen cycles as separate cycles?
 1e: Please provide a copy of your current applied eligibility and treatment criteria.

Question 2 - IVF Tender Process

2a: What is the CCG’s current model of provision?
2b: When did CCG last place its IVF service out for procurement?
2c: Since the CCG last placed its IVF service out for procurement, what market engagement exercises have taken place?
2d: How has the CCG satisfied itself that it has the best placed providers in relation to IVF?
2e: What are the CCGs commissioning intentions in relation to IVF services?
2f: Who are the providers currently under contract with the CCG for the delivery of IVF? (Please include contracts where the CCG is an associate commissioner)

Question 3   - IVF Top Up Provision

3a: What is the CCGs Policy on the Provision of Top-Up Treatments, for example: embryo glue; assisted hatching; PGS NGS; Embryoscope. How is this translated in relation to IVF and associated care?   (Please send me a copy)
3b: Are patients able to top-up when having care at both NHS and Independent Sector Providers, or do different rules apply?
3c: Do you give patients any support and guidance material on the topic of top ups?
3d: Is there an opportunity for providers to offer this guidance material?

Click here for response 

Click here for spreadsheet

 3 July 2018

891

All CCGs 

 1.Can you tell me if you currently commission a domiciliary medication review service?

2. Can you tell me if you have commissioned a domiciliary medication review service in the past?

3. Can you tell me the reasons for commissioning the current service?

4. Can you tell me why you commissioned the previous service?

5. Could you choose from the following reasons why you decided to decommission the service?

6. What are your inclusion criteria for patients involved in service?

7.Which professionals provide the service?

8. Is it one-time visit or multiple visit service?

10.What are your main outcomes to assess the quality of service?

11.Have you formally evaluated your domiciliary medication review service?

Click here for response

Click here for SDCCG info          

 5 July 2018

 893

All CCGs

 Please can I request information on the following:

• How many service users are waiting within the community mental health services for psychological therapy?

• How long are individuals on waiting lists for psychological assessments within community mental health services?

• How long are individuals on waiting lists before receiving the first appointment for psychological therapy within secondary care/community mental health services?

• What are the range of therapies your community/secondary care psychology service deliver?

Click here for response

Click here for service spec          

6 July 2018

894

All CCGs

Current A&E GP streaming service:
1 Who is the contracted provider of A&E streaming GPs.

2. What are the opening hours?

3. How many GPs do you have working at any one time?

4. What is the hourly pay?

5. What is the seniority mix?

6. How many GPs do you have and how many vacancies?

7. What proportion are: a) locums, b) from local practices c) employed by the Trust, or d) other? (If other, please explain)

Between November 1 2017 and April 30 2018:

8. How many patients were seen through A&E GP streaming?

9. What proportion were: a) dealt with in full, b) sent through to A&E, c) referred to their own GP or d) other?

To date (since launching the streaming service):

10. How many patient complaints have you received concerning A&E GP streaming?

 Click here for response
9 July 2018

895

All CCGs

Please can you share the total number of Urgent Treatment Centres due to be launched in your CCGs.

For each UTC in your CCGs, please can you provide the following information:

• UTC name
• UTC address
• It’s launch date
• Contact information (where available)
• Website (where available)

Click here for response
12 July 2018

 896

All CCGs

1. How many children and young people does your CCG currently have waiting for assessment following referral to tier 3 CAMHs services?
2. How many of these have waited for less than four weeks/between 4 and 18 weeks/18 weeks to a year/longer than a year (please break down numbers waiting according to these categories)? Please state how long the person waiting the longest has waited.
3. How many children and young people have currently been assessed as needing CAMHS tier 3 treatment but have not yet started it?
4. How many of these have waited less than 4 weeks/between 4 and 18 weeks/18 weeks to a year/more than a year in total (ie since referral, not since assessment; please break down numbers waiting according to the categories listed). Please state how long the person waiting the longest has waited.
5. Over the last year, how many referrals for CAMHS tier 3 have you had? What proportion of these are then assessed as needing tier 3 treatment?
 
 Information not held - redirected to Derbyshire Health care Foundation Trust          
 12 July 2018

 897

All CCGs

   1. A) Does the CCG provide extended GP access by offering routine GP appointments 8am-8pm, seven days a week? (Yes/No)
  B) Please state what evening and weekend routine GP access is provided in the CCG area (if any). Please only include information on routine GP appointments made available out of normal hours, not any emergency or urgent out-of-hours services.

2. How many extended access appointments are available in the CCG area on A) Saturday B) Sunday and C) weekday evenings? (please state a separate figure for A, B and C)

3. In the financial year 2017/18, what percentage of these extended access appointments were filled on A) Saturdays B) Sundays and C) weekday evenings? (please state a separate figure for A, B and C)

4. A) How many locations (ie. GP practices, health centres) within the CCG area host the extended access routine GP appointments?
   B) If possible, please provide a list of clinics which host these extended access appointments and, if applicable, state what they offer (eg. "Practice A - evenings, Saturdays & Sundays; Practice B - Sundays only”).

5. In the year 2017/18, what did the CCG spend on providing extended access to routine GP appointments?
Please include any funding received by the CCG from central bodies specifically for providing the extended access to routine appointments service, as well as any other funding spent on this by the CCG. Please do not include any money spent on emergency or urgent out-of-hours care.
             

Click here for response
 13 July 2018

 898

All CCGs

 
  1. Please can you state the main provider of children’s and young people’s community services, including physical and mental health, for NHS Southern Derbyshire CCG in each the following financial years: 2015-16, 2016-17, 2017-18, 2018-19
  2. Please can you state the CCG’s total spending on children’s and young people’s community services, including physical and mental health, in each the following financial years: 2015-16, 2016-17, 2017-18, 2018-19
  3. When does the CCG’s current main contract for these services end?
  4. Does the CCG intend to tender the contract at that point?

Click here for response

Click here for spreadsheet

 17 July 2018

 899

All CCGs

 1. a) Has your CCG clearly mandated in its providers’ service contracts that failure to comply with best practice in VTE prevention will result in consequences imposed by your CCG? (Best practice in VTE Prevention as defined by NICE Quality Standard 3: VTE Prevention, NICE Clinical Guideline 92, the VTE risk assessment National Quality Requirement, and NHS Standard Contract Service Condition 22) (Tick a box)

2. a) Has your CCG agreed a local penalty for failure to comply with the VTE risk assessment National Quality Requirement? (Tick a box)

b) Between 1 April 2017 and 31 March 2018, has your CCG imposed a penalty on providers that fail to comply with the VTE risk assessment National Quality Requirement? (Tick a box)
If ‘Yes’, please specify which providers your CCG has imposed a penalty on between 1 April 2017 and 31 March 2018 and, if the penalty was a financial sanction, please indicate the value of the sanctions imposed:

c) How do you quality assure that your providers are complying with the national obligation to perform Root Cause Analyses of all confirmed cases of hospital associated thrombosis (HAT)? (Please tick as many boxes that apply)

d) Between 1 April 2017 and 31 March 2018, has your CCG imposed any sanctions, verbal or written warnings on providers for failure to comply with the national obligation to perform Root Cause Analyses of all confirmed cases of HAT? (Please tick one box)
If ‘Yes’, please specify which providers your CCG has imposed sanctions, verbal or written warnings on between 1 April 2017 and 31 March 2018:

3. a) Does your CCG have an estimate of the cost of VTE to the NHS locally (including cost of treatment, hospital bed days, sanctions and any litigation costs) for 2017/18? (Please tick one box)
If ‘Yes’, please specify the estimated cost:

 

 Click here for response

Click here for completed survey

 18 July 2018

900

E, ND, SD 

 1) Please provide copies of any policies your CGG has on the commissioning of services for those with an FASD.

2) What services has your CCG commissioned to meet the ‘reasonable requirements’, as is your duty under Section 3 NHS Act 2006, of those in your area who have or may have Foetal Alcohol Spectrum Disorders as a result of antenatal exposure to alcohol, and what is your CCG doing to secure improvement in the physical and mental health of persons with Foetal Alcohol Spectrum Disorders and for the prevention, diagnosis and treatment of FASD (as is in your power under Section 3A NHS Act 2006)? Please release any information you hold concerning provision for:
a. prevention education following the Chief Medical Officers’ guidelines that the safest course is not to drink while pregnant or attempting to become pregnant;
b. diagnosis for both children and adults; 
c. post-diagnostic care in the years 2013- 2018 from professionals including, but not limited to, paediatricians, GPs, nurses, psychologists, occupational therapists, speech and language therapists, mental health services and other disability support services to provide specialised intervention services for patients on the FASD spectrum across their lifespan?

3) Please release any information concerning how is your CCG exercising its duty (as specified under Section 14R NHS Act 2006) to securing “continuous improvement in the quality of services provided” to individuals with Foetal Alcohol Spectrum Disorders “for or in connection with the prevention, diagnosis or treatment” of FASD?

4) What is the budget for commissioned services for FASD in the current financial year? What was the budget in financial years beginning in 2013, 2014, 2015, 2016 and 2017?

5) Please release any agreed plans for service expansion for future years.

6) Has your CCG conducted, commissioned or assisted the conduct of research into any matters relating to the causation, prevention, diagnosis or treatment of Foetal Alcohol Spectrum Disorders, as is in your powers according to Section 5 NHS Act 2006 Schedule 1 (paragraph 13).

7) Does your CCG commission services from the National FASD Clinic? If so, what is the budget for this in the current financial year?

8) Please release any information concerning ways in which your CCG is fulfilling its duty (specified under Section 14Z, NHS Act 2006) to promote education and training related to FASD?

9) Do you have a lead person in your CCG on FASD? Please provide the name and role of the person responsible.

10) Please release any information concerning the steps are you taking or have you taken (according to your duty under section 14Z2 of the NHS Act, 2006), to involve individuals with FASD or their caregivers in “planning commissioning arrangements; in the development and consideration of proposals for change; in decisions affecting the operation of commissioning arrangements where implementation would have an impact on the manner in which services are delivered or the range of services available.”?

11) How many inquiries/requests/letters have you received from medical practitioners or patients/families in your area related to FASD in the years 2013-2018?

 Click here for response
 18 July 2018

901

H, ND 

Multiple questions regarding fertility, IVF, ICSI, providers etc.

Click here for response

Click here for Hardwick response

Click here for ND response

Gamete Storage Policy

 18 July 2018

 902

H, ND, SD

 1. In the six months to 30 June 2018, please list any correspondence (including email, phone conversation, physical meeting) between the CCG and representatives of organisations Babylon Healthcare Ltd, Babylon Partners Ltd or GP at Hand, including the data and nature of the correspondence.

 
2. Please provide documentation relating to these correspondences (including email, phone conversation, physical meeting) with Babylon Healthcare Ltd, Babylon Partners Ltd or GP at Hand, including emails, notes, meeting agendas and minute.

Click here for response

Please contact CCG for further attachments

 19 July 2018

 903

H, ND

 1.       Please identify and state the name of any formulary group that your CCG was part of in 2016? This may include one or more of: a joint formulary committee, area formulary committee or equivalent formulary.

2.       On what date was Qdem’s 7-day buprenorphine transdermal patch with the product name Butec submitted to any formulary group identified in question “1” above for consideration and approval as to whether it should be included on the respective drug formulary?

3.       Where Butec has been added to your CCG’s drugs formulary or another formulary identified in question “1”, please provide any minutes that evidence what decisions were made in relation to whether to approve or reject Butec’s application.

4.       On what date was Butec first added to your CCG’s drug formulary (adopting the relevant formulary identities listed above)?

5.       Assuming the response to question “3” is positive, has any other branded generic 7-day buprenorphine transdermal patch subsequently been added, or replaced Butec on your CCG’s drug formulary? Please indicate the date on which this occurred. If the answer to this question is positive, please provide any minutes that evidence what decisions were made in relation to whether to approve or reject an subsequent supplier’s branded generic 7-day Buprenorphine transdermal patch application.

6.       Please provide a copy of any guidance your CCG possessed in 2016 that established the process by which a new drug would be considered for addition to your CCG’s drug formulary (again, adopting the relevant formulary identities listed in question “1”).

7.       Please provide any other minutes recorded by your CCG that evidence what decisions were made by your CCG’s medicines management committee or other equivalent committee at CCG level to select a preferred branded generic 7-day Buprenorphine transdermal patch.

Click here for response

 

Click here for attachment

 23 July 2018

 904

All CCGs

I was wondering if I could please request details of payments made to pharmacies for locally commissioned NHS or private services, for example smoking cessation, emergency hormonal contraception, supervised consumption of medicines, & needle exchange services.

 If you could kindly provide this in spreadsheet(s) format, with a breakdown by pharmacy (name and address), month, service, and payment, I would greatly appreciate it (if you also have the ODS code identifier for the pharmacy, then please kindly include this also). If possible, details of the most recent 12 months worth of payments.

Click here for response

SD pharmacy list

E H ND pharmacy list

 23 July 2018

 905

All CCGs

 1. The number of elective (a) spinal surgeries, (b) non-surgical treatments for lower back pain and (c) spinal cord stimulation treatments for chronic pain funded each year in 2013/14, 2014/15, 2015/16, 2016/17 and 2017/18.

2. The number of successful Individual Funding Requests (or equivalent procedure) made for each of (a) spinal surgeries, (b) non-surgical treatment for lower back pain and (c) spinal cord stimulation treatments for chronic pain funded each year in 2013/14, 2014/15, 2015/16, 2016/17 and 2017/18.

3. The number of unsuccessful Individual Funding Requests (or equivalent procedure) made for each of (a) spinal surgeries, (b) non-surgical treatments for lower back pain and (c) spinal cord stimulation treatments for chronic pain funded each year in 2013/14, 2014/15, 2015/16, 2016/17 and 2017/18.

 Click here for response
27 July 2018

907

All CCGs

 ·         Map of the assessment process in place including:

o    contact email for checklist submission

o   telephone number

o   details and copies of any additional consent forms or basic information forms

                       o details of who manages and Co ordinates the dst

·         Do you have CSU involvement in the CHC process?

·         Number of eligibility decisions within the last year which are being made within 28 days

·         Number of full working time equivalent employed for CHC and job titles

·         Number of checklists received in the past year

·         Number of checklist which resulted in a full assessment in the past year

·         Number of service users how have successfully achieved CHC funding in past year

·         Number of service users who have not been successful with CHC funding but have received some contribution from health

·         A copy of the dispute process (section 143. Of framework)

Click for Response

Consent form

Dispute resolution procedure

31 July 2018

908

All CCGs

Please can you confirm:

a. The total amount your CCG spent on all mental health services in 2017/18 including any NHS England funds spent on specialised mental health services.

b. The total amount your CCG spent on all mental health services in 2017/18 excluding any NHS England funds spent onspecialised mental health services.

c. The total amount your CCG spent on Children and Young Persons Mental Health services in 2017/18 excluding learning disabilities and eating disorders.

 Click here for response
 31 July 2018

 909

SDCCG

 Please send me the following information relating to all contracts active during Financial Year 2018/19 procured under the following Common Procurement Vocabulary (CPV) codes 85000000 and 98000000.
•         The name of the contract
•         A brief description of the contract
•         The value of the contract
•         The start date of the contract
•         The end date of the contract
•         The awarded contract provider
Click here for response
       
       
Last modified: 24/08/2018